Cargando…
Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
BACKGROUND: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011. METHODS: Eligible patients with refractory advan...
Autores principales: | Anthoney, D Alan, Naik, Jay, MacPherson, Iain RJ, Crawford, Donna, Hartley, John M, Hartley, Janet A, Saito, Tomohisa, Abe, Masaichi, Jones, Keith, Miwa, Masanori, Twelves, Christopher, Evans, TRJ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517777/ https://www.ncbi.nlm.nih.gov/pubmed/23170896 http://dx.doi.org/10.1186/1471-2407-12-536 |
Ejemplares similares
-
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
por: Propper, David, et al.
Publicado: (2016) -
Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015) -
Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
por: Brunet, Mercè, et al.
Publicado: (2022) -
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
por: Teng, Renli
Publicado: (2015) -
Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
por: Yu, Meng, et al.
Publicado: (2018)